GlassScriptPhysician profile
Kelly Wilson
NPI 1538255344
$10,894.37
in general payments reported to CMS, 2019-2025
34 companies · $472 in 2025
The $472 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $641 · 2021: $2,199 · 2022: $796 · 2023: $5,514 · 2024: $620 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $2,508 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $2,507.87 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $4,000.00 | 2023 | Slynd |
| Biohaven Pharmaceuticals, INC. | $1,334.72 | 2020-2021 | |
| Abbvie INC. | $838.50 | 2019-2025 | Vraylar, Lo Loestrin Fe, Orilissa |
| Bausch Health US, LLC | $728.73 | 2020-2025 | Aplenzin, Wellbutrin |
| Novo Nordisk INC | $673.85 | 2019-2025 | Wegovy, Saxenda |
| Lupin INC. | $317.65 | 2019-2020 | |
| Myovant Sciences INC. | $282.08 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $265.48 | 2023 | Quviviq |
| Amgen INC. | $256.43 | 2024 | Evenity, Prolia |
| Pfizer INC. | $230.51 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $225.76 | 2023-2024 | Myfembree |
| Allergan, INC. | $181.11 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $179.27 | 2021-2024 | |
| Avion Pharmaceuticals | $166.06 | 2021-2023 | Balcoltra |
| Astellas Pharma US INC | $134.08 | 2023 | Veozah, Myrbetriq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.14 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $106.25 | 2022 | |
| Axsome Therapeutics, INC. | $103.79 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $101.84 | 2020-2023 | Trintellix |
| Currax Pharmaceuticals LLC | $99.57 | 2020-2025 | Contrave |
| Myriad Women'S Health, INC. | $85.77 | 2023 | Myrisk |
| Lilly USA, LLC | $81.82 | 2019-2024 | Zepbound |
| Hologic Sales and Service, LLC | $63.35 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Millicent US INC | $56.13 | 2021-2024 | Femring, Intrarosa |
| Therapeuticsmd, INC. | $53.12 | 2019-2020 | |
| Agile Therapeutics, INC. | $48.62 | 2022-2023 | Twirla |
| Vertical Pharmaceuticals, LLC | $32.60 | 2019 | |
| Ibsa Pharma INC. | $28.09 | 2020 | |
| Mycovia Pharmaceuticals, INC. | $26.07 | 2023 | Vivjoa |
| Exact Sciences Corporation | $20.97 | 2023 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $16.03 | 2021 | |
| Eisai INC. | $15.13 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.77 | 2019 | |
| Scynexis, INC. | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.